GangaGen
Bangalore
About GangaGen
GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.3M
- Funding stage: Seed
- Last round: Grant (Dec 2024)
- Website: gangagen.com
- Phone: +1-650-8569642
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/gangagen-150094 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.